Targeted protein degradation harnesses the cell's own machinery to eliminate disease-causing proteins, opening new therapeutic possibilities.
Proteolysis targeting chimeras recruit E3 ligases to degrade undruggable targets.
Small molecules that stabilize protein-protein interactions leading to degradation.
Degrade transcription factors, scaffolding proteins, and other challenging targets.
Target oncogenic proteins resistant to traditional small molecule inhibition.
Clear toxic protein aggregates in Alzheimer's, Parkinson's, and ALS.
Expand the degrader toolkit with novel E3 ligase recruiters and mechanisms.
Patient Analog connects cutting-edge research with biotech intelligence infrastructure.
Explore Patient AnalogThis premium domain is available for acquisition. Submit your inquiry or make an offer below.